GLAXO GlaxoSmithKline Pakistan Limited
Latest results: FY2025 · Dec 2025 Q2 FY2026 · Apr – Jun 2026
Last close · 16 Oct 2026
Rs 312.45 +0.19%
Annual · FY2006 – FY2025
GlaxoSmithKline Pakistan Limited (GLAXO) financial ratios
GlaxoSmithKline Pakistan Limited earned a net margin of 15.2% in FY2025 against a five-year average of 9.5% (Pharmaceuticals median 9.4%). Return on equity was 32.4%, compared with a sector median of 21.7%. The current ratio stood at 2.32× and debt was 1.1% of equity. Cash took about 142 days to cycle through receivables, inventory and payables.
FY2025 vs the Pharmaceuticals median
- Gross margin
- 37.0%
- Sector median 37.0%
- Operating margin
- 24.9%
- Sector median 17.3%
- Net margin
- 15.2%
- Sector median 9.4%
- Return on equity (ROE)
- 32.4%
- Sector median 21.7%
- Return on assets (ROA)
- 20.9%
- Sector median 11.7%
- Current ratio
- 2.32×
- Sector median 1.79×
- Debt to equity
- 1.1%
- Sector median 5.8%
- Asset turnover
- 1.38×
- Sector median 1.26×
- Dividend payout ratio
- 38.1%
- Sector median 32.8%
Median of the 14 companies in the sector with the figure for their latest fiscal year.
| Rs mn | FY2025 Jan – Dec 2025 | FY2024 Jan – Dec 2024 | FY2023 Jan – Dec 2023 | FY2022 Jan – Dec 2022 | FY2021 Jan – Dec 2021 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||
| Gross margin | 37.0% | 25.1% | 6.9% | 17.5% | 26.9% | |||||||||||||||
| EBITDA margin | 27.0% | 18.6% | 5.2% | 25.7% | 22.2% | |||||||||||||||
| Operating margin | 24.9% | 16.7% | 3.3% | 9.9% | 20.1% | |||||||||||||||
| Pre-tax margin | 25.3% | 17.1% | 4.4% | 12.2% | 20.3% | |||||||||||||||
| Net margin | 15.2% | 10.7% | 1.1% | 5.9% | 14.6% | |||||||||||||||
| Effective tax rate | 39.9% | 37.6% | 75.5% | 51.8% | 27.9% | |||||||||||||||
| Returns | ||||||||||||||||||||
| Return on equity (ROE) | 32.4% | 26.2% | 2.5% | 11.7% | 27.8% | |||||||||||||||
| Return on assets (ROA) | 20.9% | 15.7% | 1.4% | 7.5% | 18.9% | |||||||||||||||
| Return on invested capital (ROIC) | 32.2% | 26.0% | 2.5% | 11.7% | 27.8% | |||||||||||||||
| Liquidity | ||||||||||||||||||||
| Current ratio | 2.32× | 2.06× | 1.74× | 1.82× | 2.28× | |||||||||||||||
| Quick ratio | 1.43× | 1.18× | 0.85× | 0.94× | 1.43× | |||||||||||||||
| Leverage | ||||||||||||||||||||
| Debt to equity | 1.1% | 0.6% | 0.7% | 0.3% | 0.3% | |||||||||||||||
| Debt to capital | 1.1% | 0.6% | 0.7% | 0.3% | 0.3% | |||||||||||||||
| Debt to assets | 0.7% | 0.4% | 0.4% | 0.2% | 0.2% | |||||||||||||||
| Assets to equity | 1.55× | 1.67× | 1.72× | 1.57× | 1.47× | |||||||||||||||
| Efficiency | ||||||||||||||||||||
| Asset turnover | 1.38× | 1.47× | 1.35× | 1.27× | 1.30× | |||||||||||||||
| Receivable days days | 66 | 58 | 58 | 44 | 26 | |||||||||||||||
| Inventory days days | 116 | 104 | 96 | 97 | 91 | |||||||||||||||
| Payable days days | 40 | 44 | 32 | 19 | 30 | |||||||||||||||
| Cash conversion cycle days | 142 | 118 | 122 | 123 | 86 | |||||||||||||||
| Dividends | ||||||||||||||||||||
| Dividend payout ratio | 38.1% | 48.7% | 0.0% | 0.0% | 41.6% | |||||||||||||||
| Earnings retention rate | 0.62× | 0.51× | 1.00× | 1.00× | 0.58× | |||||||||||||||
Ratios as reported for each fiscal year; returns are on average equity / assets. Debt ratios are percentages; turnover in times; working-capital measures in days.
GLAXO: frequently asked questions
What is GLAXO's EPS?
GlaxoSmithKline Pakistan Limited reported basic earnings per share of Rs 31.48 for FY2025 (Jan – Dec 2025). Over the trailing twelve months (TTM to Jun 2026) EPS was Rs 32.69.
What is GLAXO's P/E ratio?
At the closing price of Rs 312.45 on 16 Oct 2026, GLAXO trades at a P/E of 9.6× based on EPS of Rs 32.69 (TTM to Jun 2026).
Does GLAXO pay dividends?
Yes. GlaxoSmithKline Pakistan Limited declared a dividend of Rs 17.00 per share for FY2025. It has paid a dividend in each of the last 2 years. At Rs 312.45 that is a dividend yield of 5.4%.
What was GLAXO's revenue and profit in FY2025?
GlaxoSmithKline Pakistan Limited reported revenue of Rs 65.9 bn and profit attributable to shareholders of Rs 10.0 bn for FY2025 (Jan – Dec 2025).
What is GLAXO's book value per share?
GlaxoSmithKline Pakistan Limited's book value per share was Rs 105.74 at the end of FY2025. The shares trade at 2.89× book value.
Information only, not investment advice.